Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6533
    +0.0010 (+0.16%)
     
  • OIL

    84.12
    +0.55 (+0.66%)
     
  • GOLD

    2,360.20
    +17.70 (+0.76%)
     
  • Bitcoin AUD

    98,111.34
    +995.84 (+1.03%)
     
  • CMC Crypto 200

    1,387.13
    -9.40 (-0.67%)
     
  • AUD/EUR

    0.6089
    +0.0015 (+0.25%)
     
  • AUD/NZD

    1.0982
    +0.0025 (+0.23%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,116.39
    +37.53 (+0.46%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,049.63
    +132.35 (+0.74%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Could This Drug News Lift AbbVie's Stock?

Could This Drug News Lift AbbVie's Stock?

Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.